// App-Quantinova.ai

145 : Nadunolimab inhibits IL-1α/β-induced CXCR1/2 ligand expression and reduces serum levels of CXCL1 and CXCL5 in NSCLC and PDAC patients

Researchers

Presenter

  • Camilla Millrud

Principal Investigators

  • Elin Gyllenbäck

  • Petter Skoog

  • Annika Sanfridson

  • David Liberg

Medical Centers

  • Cantargia, Lund, Sweden

Locations

  • Sweden

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

  • Non Small Cell Lung cancer

  • Microphthalmia, syndromic, 9

Biomarkers

  • Peripheral blood mononuclear cell

  • C-X-C motif chemokine ligand 5

  • C-X-C motif chemokine ligand 8

  • C-X-C motif chemokine receptor 1

  • Chemokine (C-X-C motif) ligand 1

  • Interleukin 1 alpha

  • Interleukin 1 beta

Drug/Treatment

  • Gemcitabine

  • Paclitaxel

  • Cisplatin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT03267316</

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved